CS Paper Radar

AI-Enhanced Hyperspectral Imaging for Intraoperative Detection of Low-Grade Glioma: A Clinical Study

Siri Willems, Ishika Jain, Jens De Winne, Siri Luthman, Hamed Zivari Adab, Roeland Vandebriel, Anna Alperovich, Xiaohan Zhang, Ben Stoffelen, Tom De Schepper, Lien Solie, Steven De Vleeschouwer

cs.CV cs.AI ·submitted 2026-10-13 08:27 UTC · v1

Abstract

Current image-guided neuronavigation techniques, such as intraoperative MRI and ultrasound, are limited by high costs, limited sensitivity and operational complexity. There is a clear need for more efficient systems to enhance intra-operative tumor detection and improve patient outcomes for intrinsic brain tumor resection. Whereas previous intraoperative brain HSI studies have predominantly investigated high-grade gliomas, glioblastomas, or mixed-grade cohorts, this clinical study focuses specifically on low-grade gliomas (LGGs). LGGs strongly resemble normal brain under white light conditions on the operative microscope. This study characterizes spectral differences between healthy and tumor tissue and provides a paired comparison of HSI- and RGB-based classification at matched tissue locations and under identical patient-level data splits. Tumor regions showed consistently lower reflectance, which may be associated with differences in hemoglobin concentration and oxygenation. A range of classification models was evaluated. The 3D CNN, which integrates spectral and spatial features, achieved the highest median ROC-AUC of 74.5%, compared with 67.9% for the spectral-only XGBoost model and 64.0% for the RGB-based model. These results support further investigation of HSI for low-grade glioma classification and quantify its performance relative to conventional RGB imaging in this cohort.

Closest papers

Nearest neighbours by meaning across the whole index.

A new MRI-based feature for quantifying the Diffuse Low-Grade Glioma brain infiltration and discriminating patterns of patients

eess.SP stat.AP ·2026-10-05 ·Jean-Marie Moureaux, Sophie Wantz-M{é}zi{è}res, Cyril Brzenczek, Marie Blonski, Luc Taillandier
published similarity 0.64
Abstract

Gliomas are the most common type of primary brain tumors. Diffuse low-grade gliomas (DLGGs) are slow-growing tumors that are often minimally symptomatic for a long period of time. They progress to a higher grade, resulting in the patient's death. Treatments include surgery, chemotherapy and radiation therapy to control tumor progression. Responses to treatments are highly variable among patients. Furthermore, the diffuse component of this tumor entity has been observed but is not yet well measured. Here, we propose a new variable to quantify glioma morphology, called ESVR (Extra Sphere Volume Ratio). We use then a machine learning approach to study the importance of different variables for discriminating patterns of patients: patient-specific variables, genetic alterations of tumor tissue, and some image-based variables like ESVR and the volume of the tumor, obtained by MRI analysis. Our machine learning approach shows that the patient's age and ESVR at diagnosis, as well as the pathology results seem to play an important role. Taking the highlighted variables into account could thus help to model the tumor behavior. In association with other classical biomarkers, our new ESVR feature could help the clinician to manage the treatment, as it carries significant information in terms of aggressivity of the DLGG.

0.48

BrainAid: Efficient Brain Tumor Detection Using Lightweight CNNs and Explainable AI for Resource-Constrained Environments

cs.CV ·2026-10-10 ·Sai Sriram Gonthina, Ross Gore, Bikash Chandra Singh, Pronaya Bhattacharya, Sachin Shetty +2 more
similarity 0.61
Abstract

A brain tumor is an unusual growth of cells in the brain that can be cancerous or not, affecting normal brain function and causing serious risk to health. Existing solutions for brain tumor classification, such as expert manual evaluations of magnetic resonance imaging (MRI) scans, are generally inconsistent as different professionals have different criteria and can be resource-intensive, leading to delayed diagnoses. Additionally, while deep learning models have demonstrated potential, they typically require significant computational resources, motivating the need for more efficient and accessible diagnostic tools that can be deployed in real-time healthcare settings. To address these limitations, this study presents BrainAid, which makes efficient use of Convolutional Neural Networks (CNNs) and Vision Transformers (ViTs) for effective classification of four-class classification of glioma, meningioma, pituitary tumor, and no-tumor MRI scans, outperforming all the standard models such as VGG16, Inception-V3, ResNet-50 and so, while integrating Explainable AI (XAI) to improve interpretability. The BrainAid is trained to classify tumors with a high precision of 98%, achieving an F1 score of 98% and an accuracy of 98% using publicly available dataset. The model is deployed on a Raspberry Pi, demonstrating efficiency in low-resource environments. This system shows the feasibility of real-time, edge-based tumor classification, providing quick diagnostic support for medical professionals and enhancing patient care in resource-limited healthcare facilities and underserved areas.

0.07

A Trustworthy Clinical Decision Support Framework for Brain Tumor MRI Classification: Integrating Attention-Guided Learning, Explainable AI, and Out-of-Distribution Validation

cs.CV cs.AIcs.LG ·2026-10-06 ·Arjun Kumar Gupta, Harminder Pal Monga
publishedbenchmark similarity 0.61
Abstract · Accepted for presentation at the IC3AI-2026 IEEE conference in Dec 2026. It has been accepted/selected but is not yet published. 6 pages, 4 …

Deep learning models for brain tumor diagnosis need to do more than achieve high classification accuracy. For practical use, they should also provide understandable predictions, recognize unsuitable inputs, and work within a usable clinical system. This paper presents a framework for classifying brain MRI into four categories: glioma, meningioma, pituitary tumor, and no tumor. The model uses InceptionResNetV2 with a Convolutional Block Attention Module (CBAM), while Grad-CAM provides visual explanations of its predictions. A two-stage out-of-distribution (OOD) mechanism screens unsuitable inputs using an initial grayscale check followed by Mahalanobis distance, softmax confidence, and predictive entropy. These components are brought together in NeuroScan AI, a real-time web application. Evaluated on a Mendeley brain tumor MRI dataset of 12,064 images, the framework achieved 98.70% validation accuracy, 96.73% test accuracy, and a macro-average AUC of 0.9965. The OOD pipeline achieved 99% detection accuracy on a preliminary 100-image benchmark. Grad-CAM visualizations showed qualitative correspondence with clinically established tumor locations across all four classes. Overall, the work brings classification, explainability, input validation, and deployment into one framework, while recognizing that broader clinical and OOD validation is still required.

0.25

GliomaINK: A Tumor and Anatomy Conditioned Flow Matching Framework for 3D MRI Sequence Synthesis in Glioma Patients

eess.IV cs.CVq-bio.TO ·2026-10-16 ·Moinak Bhattacharya, Annie Singh, Mohammad Chaudhry, Prateek Prasanna, Gagandeep Singh
similarity 0.59
Abstract

Background: Incomplete multiparametric MR examinations limit glioma characterization and downstream AI tools. Generative models can synthesize missing MRI sequences, but anatomical structure and clinically relevant tumor features are challenging to preserve. We propose GliomaINK, an anatomy-guided conditional flow matching framework for cross-sequence 3D brain MRI synthesis. Methods: A 3D SwinUNETR predicted the conditional velocity field while an auxiliary topology-preserving loss encouraged structural consistency. The model was trained on 1,083 patients from the BraTS-AG dataset and independently tested on an in-house clinical cohort. Downstream tasks include image quality, tumor segmentation, IDH1 mutation-status prediction, and overall survival prediction. Two radiologists independently evaluated the anatomical fidelity, pathological representation, and overall image quality of the synthesized images. Results: GliomaINK exhibited the highest PSNR across all six MRI translation directions in both evaluation cohorts. In the BraTS-AG test set, the PSNR reached $25.64\pm0.55$ dB for the T2W-to-T1C synthesis, compared with $13.78\pm0.32$ dB for Pix2Pix and $18.90\pm0.53$ dB for SPADE. For downstream tumor segmentation, the method showed strong performance across tumor subregions with Dice scores reaching $0.928\pm0.014$ for edema, and $0.885\pm0.040$ for enhancing tumor. For the IDH1 mutation-status prediction, GliomaINK achieved the highest AUROC score in four of the six sequence configurations, reaching $0.827\pm0.088$. Conclusion: Anatomy-guided conditional flow matching enables high-fidelity cross-sequence glioma MRI synthesis demonstrating potential for preservation of clinically relevant information in synthesized MRI and improving downstream tasks.

0.18

Benchmarking CNNs, Vision Transformers, and Foundation Models for Explainable Brain Tumor MRI Classification: Calibration, Decision Analysis, and External Validation

cs.CV ·2026-11-09 ·Akwasi Asare
similarity 0.58
Abstract · Under review at Scientific Report Journal, Springer

Deep learning models for brain tumor MRI classification are usually compared by accuracy alone, on public datasets whose independence is rarely checked. We benchmarked six architectures: two convolutional networks (EfficientNetV2-M and ConvNeXt-V2-Tiny), two vision transformers (Swin-V2-S and ViT-L/16), and two foundation models (DINOv2-L and MedSigLIP-448), for four-class classification of 7,216 public MRI images. We assessed accuracy, calibration, explainability, ensembles, and decision curves, with every fitted quantity estimated on validation data only. Pixel-verified duplicate screening showed that 36% of the test images had a near-duplicate in the training data. Test accuracy ranged from 94.5% to 95.6%, with no pairwise difference after Holm correction, and fell to 90.3% to 91.7% on the 773 test images free of duplicates and shared patients. Ensembles did not outperform the best single model. Attribution maps passed a model-randomization test but localized expert-annotated tumors poorly. On 1,675 external BDNeuro-MRI images that did not duplicate the training data, accuracy ranged from 77.6% (MedSigLIP-448) to 95.0% (ViT-L/16), and 12 of 15 pairwise differences were significant. Internal accuracy on this public collection therefore did not distinguish the architectures, whereas the duplicate-filtered external test did.

0.15

A Tumour-Aware Multimodal Framework for Explainable Prediction of IDH Mutation in Gliomas from Multi-Sequence MRI

eess.IV cs.CV ·2026-11-13 ·Tahsien Al-Quraishi, Waseem Alwan Zaboon, O. S. Albahri, Raza Nowrozy
similarity 0.57
Abstract · 45 pages, 12 figures, 4 tables. Preprint of an article submitted for consideration in International Journal of Information Technology & Deci…

Accurate prediction of isocitrate dehydrogenase (IDH) mutation status is essential for glioma diagnosis, prognosis, and treatment planning. Although recent deep learning approaches have demonstrated promising performance, many rely on whole-brain feature extraction and provide limited interpretability. This study proposes a tumour-aware multimodal framework for explainable, non-invasive prediction of IDH mutation status from multiparametric magnetic resonance imaging (MRI). The proposed framework integrates four MRI sequences (T1, T1CE, T2, and FLAIR), tumour subregion segmentation, quantitative radiomic descriptors, and clinical information within a unified deep learning architecture. An ablation study was conducted to evaluate the contribution of tumour-aware learning, radiomic features, and clinical variables. Model performance was assessed using multiple complementary evaluation metrics, including accuracy, precision, recall, F1-score, balanced accuracy, receiver operating characteristic analysis, confusion matrix evaluation, and Grad-CAM visualisation. Experimental results demonstrated that the proposed multimodal framework consistently outperformed the baseline MRI-only model, with the Clinical Fusion model achieving the strongest overall predictive performance. The integration of tumour-aware learning, radiomic descriptors, and clinical information progressively improved classification performance, while Grad-CAM visualisations indicated that the model predominantly focused on biologically relevant tumour regions. These findings suggest that tumour-aware multimodal feature integration enables accurate, interpretable, and non-invasive molecular profiling of gliomas and provides a promising foundation for future clinical decision support in precision neuro-oncology.

0.12

Explainable and CPU-Efficient Brain Tumor Classification from MRI Using Two-Phase EfficientNetB3 Fine-Tuning

cs.CV ·2026-11-18 ·Deepro Das, Saad Kabir Uddin, Mohammad Alauddin, Bornali Sarker, Thasnim Akhter
similarity 0.57
Abstract · 6 pages, 5 figures, 6 tables

Brain tumors are among the most lethal neurological disorders, with over 308,000 new diagnoses annually worldwide. Accurate classification of tumor type from Magnetic Resonance Imaging (MRI) scans is critical for treatment planning; however, manual radiological interpretation is time-consuming and prone to inter-observer variability. This paper proposes an automated deep learning pipeline for four-class brain MRI classification (glioma, meningioma, no tumor, and pituitary tumor) using EfficientNetB3 transfer learning with a custom classification head. A two-phase training strategy is adopted: Phase 1 trains the head with a frozen backbone (best validation accuracy: 92.77%), and Phase 2 selectively fine-tunes the top 37 layers at a 100x reduced learning rate (best validation accuracy: 94.91%). On an independent balanced test set of 1,600 MRI images, the system achieves 90.62% overall accuracy and a macro-average AUC of 0.9854. Gradient-weighted Class Activation Mapping (Grad-CAM) is integrated for class-discriminative visual explainability. The proposed system simultaneously addresses three dimensions absent in prior work: high accuracy, CPU-only computational efficiency, and clinical interpretability.

0.17

A Vision-Language Foundation Model for Precise and Comprehensive Brain Tumor Diagnosis from Preoperative Multimodal Data

cs.CV cs.AI ·2026-09-15 ·Yinong Wang, Jianwen Chen, Zhou Chen, Shuwen Kuang, Haoning Jiang +26 more
code/data similarity 0.57
Abstract · 94 pages, 22 Figures, supplement files, Project page link: https://hku-healthai.github.io/brainvlm_project.github.io/

We developed BrainVLM to classify all 12 World Health Organization (WHO) 2021 brain tumor types. BrainVLM integrates an uncertainty quantification strategy to indicate prediction reliability and a module for generating radiology reports to elucidate the clinical rationale. BrainVLM was trained on multi-modal data (MRI scans, demographics, and radiology reports) from 40,043 individuals. It was validated on 5,211 patients with pathologically confirmed brain tumors, including 3,877 held-out patients from the primary hospital and 1,334 patients from 11 independent hospitals. We further conducted two proof-of-concept studies to validate its clinical utility in AI-clinician workflows: 1) a blinded multireader study where 12 neuroradiologists across varying experience levels interpreted 248 retrospective cases with or without AI assistance, and 2) a real-world prospective study in which 1,009 patients were independently and blindly assessed by BrainVLM and radiologists before surgery. Additionally, we demonstrated BrainVLM's utility in preoperative molecular subgroup prediction for adult-type diffuse gliomas, using a multi-center cohort of 632 patients. In primary evaluation, BrainVLM achieved an area under the curve (macro-AUC) of 0.85 (95% CI: 0.84-0.86), and an F1 score of 0.82 (95% CI: 0.81-0.83), surpassing neuroradiologists (F1 = 0.80 (95% CI: 0.79-0.81)). In external validation across 11 centers, BrainVLM achieved an AUC = 0.80 (95% CI: 0.79-0.82) and F1 = 0.75 (95% CI: 0.73-0.78), compared with F1 = 0.71 (95% CI: 0.69-0.73) for neuroradiologists. In prospective real-world evaluation, BrainVLM maintained performance comparable to neuroradiologists. The BrainVLM project page is available at https://hku-healthai.github.io/brainvlm_project.github.io/.

0.35